Market Overview

ChemoCentryx Says Glaxo's Top-Line Results from SHIELD-1 Phase III Study of Vercirnon Did Not Meet Primary Endpoint

Share:
Related GSK
7 Trends Drug Investors Should Know
Top 4 Large-Cap Stocks In The Drug Manufacturers Industry With The Highest ROE
The Weekender (Seeking Alpha)
Related CCXI
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3
Biggest Gainers From Friday, December 12, 2014

ChemoCentryx, Inc. (Nasdaq: CCXI) reports that GlaxoSmithKline (NYSE: GSK) announced today that the first of four Phase III studies, the SHIELD-1 study, investigating vercirnon, an inhibitor of the chemokine receptor known as CCR9, in patients with moderate-to-severe Crohn's disease did not achieve the primary endpoint of improvement in clinical response and the key secondary endpoint of clinical remission. The rates of serious adverse events and withdrawals due to adverse events were similar among all treatment groups including the placebo group, with a trend in dose-dependent increases in overall adverse event rates. GSK has indicated that it intends to continue to explore the safety and efficacy results to inform decisions about the clinical development program for vercirnon. New recruitment and dosing in the ongoing clinical program has been suspended pending further review of the SHIELD-1 results.

Posted-In: News FDA

 

Related Articles (GSK + CCXI)

Around the Web, We're Loving...